BIOREG ServicesBIOREG Services
  • Home
  • About Us
  • Services
    • Regulatory Strategy
    • Pre-approval Services
    • Regulatory Applications
    • Post-approval Services
    • Quality support
  • EU-MDR
  • Our clients
  • Blog
  • Contact
  • Home
  • About Us
  • Services
    • Regulatory Strategy
    • Pre-approval Services
    • Regulatory Applications
    • Post-approval Services
    • Quality support
  • EU-MDR
  • Our clients
  • Blog
  • Contact

Blog

  • Home
  • Blog
  • Presenting a BioReg Partner | Authorized Representative, mdi Europa GmbH

Presenting a BioReg Partner | Authorized Representative, mdi Europa GmbH

  • Posted by Daniel Albahari
  • Categories Blog
  • Date June 23, 2020

As you know, placing a new medical device on the market is the end result of long and laborious team work. 

A medical device team can vary depending on the product type but it will almost always, without exception, include an innovator, an IP lawyer, a regulatory affairs and quality specialist, an R&D expert, a formulator, an engineer and a preclinical, clinical, marketing and business development expert.

To provide the best solution for clients, BioReg collaborates with top-quality, experienced and trusted partners and associates who have been carefully chosen over the years. 

In this blog, we are delighted to present to you our long-term service partner – EU Authorized Representative, mdi Europa GmbH. 

If I had to summarize in just one sentence the work that mdi Europa undertakes led by Michael Sander, I would probably say: ‘You always get more than you expect in a professional, thoughtful, timely and friendly manner. Thank you, Michael!’

More about the company

mdi Europa GmbH was founded in March 2000 to provide medical device manufacturers world-wide with flexible and well-adjusted service packages to assist clients to comply with EU legislation. mdi Europa GmbH acts as a European Authorized Representative (as defined in the Medical Devices Regulation (EU) 2017/745 (MDR), the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR), the Medical Devices Directive 93/42/EEC (MDD) and the In Vitro-Diagnostic Medical Devices Directive 98/79/EC (IVDD)) for a wide range of companies – from start-ups to established corporations throughout the world.

The role of an EU Authorized Representative

European medical devices legislation stipulates the necessity of a European Authorized Representative, also known as EU Auth. Rep., EC Rep or AR, for manufacturers who don’t have their own location in Europe. EU Authorized Representatives act on behalf of manufacturers to undertake, among other matters, communication with the competent authorities. 

If your company needs an Authorized Representative in the EU, you can contact mdi Europa directly through the company website www.mdi-europa.com or via email: michael.sander@mdi-europa.com. 

See also mdi Europa’s new article on Clinical evaluation and equivalence – using literature under the MDR using this link: https://mdi-europa.com/clinical-evaluation-and-equivalence-using-literature-under-the-mdr/

Article Summary: Using literature for clinical evaluation was a common approach for setting up clinical evaluations under the MDD. This article discusses the new MDCG 2020-5 guidance document which illustrates to what extent clinical data from equivalent devices may be used for clinical evaluations under the MDR.

Please feel free to contact us directly – daniel.albahari@bioregservices.com – if you wish to learn more about the role of an AR or you have any other MDR–related question.

  • Share:
Daniel Albahari

    Previous post

    About the Class I MDR grace period & significant changes
    June 23, 2020

    Next post

    Devices without a medical purpose: how do they fit into the MDR?
    October 13, 2020

    You may also like

    • new-member
      Introducing our new BioReg member – Jelena Markovic LL. B. & Literature Clinical Evaluation Report (CER) Expert
      29 January, 2021
    • breast-implants
      Devices without a medical purpose: how do they fit into the MDR?
      13 October, 2020
    • laboratory-woman-testing
      About the Class I MDR grace period & significant changes
      26 March, 2020

    Search

    WEEKLY NEWSLETTER

    Subscribe NOW and get useful blogs every week.

    Latest Posts

    Introducing our new BioReg member – Jelena Markovic LL. B. & Literature Clinical Evaluation Report (CER) Expert
    29Jan2021
    Breast implants
    Devices without a medical purpose: how do they fit into the MDR?
    13Oct2020
    Presenting a BioReg Partner | Authorized Representative, mdi Europa GmbH
    23Jun2020
    bioreg services regulation affairs for startup companies

    We are a regulatory affairs consulting firm dedicated to providing full regulatory support to medical device and biotechnology companies.

    Address: 10 Shonei Halachot St., Old City, Jerusalem
    Phone: +972-54-689-6868
    Email 1: info@bioregservices.com
    Email 2: daniel.albahari@bioregservices.com

    DISCLAIMER

    Although we believe the information provided on our website is correct, BIOREG Services is not responsible for its accuracy.

    The web pages are for the public use as background information, and are not provided as regulatory advice whatsoever.

    Links to other websites are provided as of possible interest, but BIOREG Services is not responsible for the accuracy of their content.

    QUICK LINKS

    About Us
    EU-MDR Help
    Our Clients
    Frequently Asked Questions

    Blog
    Contact

    All Rights Reserved by Avokado.

    • Privacy
    • Sitemap